Mortality in schizophrenia: a measurable clinical endpoint
about
Suicide and schizophrenia: a systematic review of rates and risk factorsCardiac Autonomic Dysfunction in Patients with Schizophrenia and Their Healthy Relatives - A Small ReviewSystematic review of atomoxetine data in childhood and adolescent attention-deficit hyperactivity disorder 2009-2011: focus on clinical efficacy and safety.Five-year mortality in a cohort of people with schizophrenia in Ethiopia.Increased mortality in schizophrenia due to cardiovascular disease - a non-systematic review of epidemiology, possible causes, and interventions.Can we really prevent suicide?Horizon 2020 priorities in clinical mental health research: results of a consensus-based ROAMER expert survey.Life expectancy and death by diseases of the circulatory system in patients with bipolar disorder or schizophrenia in the Nordic countries.Breast Cancer Stage and Treatment Among Ohio Medicaid Beneficiaries With and Without Mental Illness.Cardiometabolic risk indicators that distinguish adults with psychosis from the general population, by age and gender.Is schizophrenia a neurodegenerative disease? Evidence from age-related decline of brain-derived neurotrophic factor in the brains of schizophrenia patients and matched nonpsychiatric controls.Mortality after hospital discharge for people with schizophrenia or bipolar disorder: retrospective study of linked English hospital episode statistics, 1999-2006Suicidal behavior in the older patient with schizophrenia.How does a history of psychiatric hospital care influence access to coronary care: a cohort study.Eight-year trends of cardiometabolic morbidity and mortality in patients with schizophrenia.Physical activity preferences of individuals diagnosed with schizophrenia or bipolar disorderReliability, validity and factorial structure of the Arabic version of the international suicide prevention trial (InterSePT) scale for suicidal thinking in schizophrenia patients in Doha, Qatar.Epidemiology and Treatment Guidelines of Negative Symptoms in Schizo-phrenia in Central and Eastern Europe: A Literature Review.Protocol for a systematic review of telephone delivered psychosocial interventions on relapse prevention, adherence to psychiatric medication and health risk behaviours in adults with a psychotic disorderInequalities in lung cancer care of elderly patients with schizophrenia: an observational cohort study.The interactive effects of negative symptoms and social role functioning on suicide ideation in individuals with schizophrenia.Effects of switching from olanzapine, quetiapine, and risperidone to aripiprazole on 10-year coronary heart disease risk and metabolic syndrome status: results from a randomized controlled trial.Mental illness and use of screening mammography among Medicaid beneficiariesEarly death in those previously hospitalised for mental healthcare in Scotland: a nationwide cohort study, 1986-2010.Mortality Rates in Users of Typical and Atypical Antipsychotics: A Database Study in PolandPsychiatrists' follow-up of identified metabolic risk: a mixed-method analysis of outcomes and influences on practicePost-stroke mortality, stroke severity, and preadmission antipsychotic medicine use--a population-based cohort study.Minimizing cardiovascular adverse effects of atypical antipsychotic drugs in patients with schizophrenia.Cardiometabolic comorbidities, readmission, and costs in schizophrenia and bipolar disorder: a real-world analysis.Women and psychosis.A critical review of major mortality risk factors for all-cause mortality in first-episode schizophrenia: clinical and research implications.The multidimensional nature of metabolic syndrome in schizophrenia: lessons from studies of one-carbon metabolism and DNA methylation.Pharmacological and psychosocial management of mental, neurological and substance use disorders in low- and middle-income countries: issues and current strategies.A review on schizophrenia and relapse--a quest for user-friendly psychopharmacotherapy.The onset and offset of psychosis--and what happens in between--a commentary on ‘Reappraising the long-term course and outcome of psychotic disorders: the AESOP-10 Study’ by Morgan et al. (2014).Paliperidone palmitate: Japanese postmarketing mortality results in patients with schizophrenia.Smoking Cessation in Individuals With Serious Mental Illness: A Randomized Controlled Trial of Two Psychosocial Interventions.Antipsychotic medication and long-term mortality risk in patients with schizophrenia; a systematic review and meta-analysis.Predictors of smoking cessation group treatment engagement among veterans with serious mental illness.Increased cardiovascular risk in patients with severe mental illness.
P2860
Q22241794-BBF4DCB7-EAF5-483E-8479-6BB4354D5026Q26822901-4D55C0D4-E4BD-461A-846C-3D8A55A9D495Q30593927-5ADF5013-5ADC-4AC7-9011-8EFDD0FC02F9Q34045160-CE71EF11-E594-4313-9F1F-660860ED248BQ34248044-EF2669A8-C54B-46A1-B1B0-06194E471136Q34300877-7202D199-B85D-48DA-94A1-AA3104625D4AQ34412179-F5C807FA-C309-45E7-9BC3-AAF25C972D09Q34796516-C8BD9DBA-8F42-4510-B7DF-12182AED9AE7Q34968939-C9C8B27B-5B52-4824-860F-E3FCF2122651Q35075344-544D28C6-1E82-42D0-927A-5D9C51A9BFE8Q35143317-3B8DB095-8480-4F6E-A0A6-6FE15E5C3C20Q35211109-B88FD42A-B5C6-4814-B495-4A277DD5A702Q35414138-944BA07B-B46A-44AF-A037-692F33DF2F73Q35882022-1E1060A9-0C58-4163-A1B3-D6B08CCBF9B3Q36060449-E32D3350-E798-4393-B1D9-7A6E8564FA71Q36074188-F60AD09B-4ED7-4F93-A626-26A744397708Q36215160-53704BD2-80AC-4048-A975-49D65FB03211Q36232324-8159AC40-15E2-4F53-968C-FB447DFFCAA3Q36406181-DE8FA3CC-A998-4371-8742-05010A707587Q36561220-60BF4F46-14C6-44E4-8081-DFB04E4A272FQ36602605-8BBC4D8C-0F5C-4DE6-80BC-F7CED7143B12Q36756154-14880C6D-81CB-4996-A903-E6DF1F8AF5DDQ36781692-624D3952-14D1-43AD-9D4B-F4099B298155Q37065070-079060F5-6E6F-4C16-82BD-F09C4DD7A791Q37297922-7B2138C3-EE28-4CF7-A6B1-1B4F784926B3Q37304238-4A905C3E-9CB6-4E1D-ADC0-4638F3B575BBQ37452537-95D6EBF3-E650-4F7C-B658-C5F1F9AA34EEQ37598547-9C3BD8E6-1932-44A8-BF0E-A592B41BFDD8Q37635208-CAB28AA3-4120-415A-AB04-5FCCD1F53FF6Q37989182-A0D6F10B-D241-4C6B-B6B4-F663F3283A74Q37998841-F90649B1-DD58-479E-8D4B-847E046527E2Q38113237-728E9651-F9C6-4A3E-91BA-446C14839CA8Q38133770-5753C865-3070-448E-8C32-9248164B3214Q38233228-EDFF9DDE-1572-4BC0-B956-E0C6E0B8D6DFQ38234436-F958AAFC-1053-43F3-B247-BE371F1C0A0EQ38855605-35AE39D6-EAEF-42E9-BB4F-24A7671D739DQ38954477-9C0967F8-173D-429B-8BCD-92D62725FF3BQ39233778-CD7EBAD3-7DE0-4299-9512-57FA30297437Q40114821-DD429172-F3AA-43BD-9D1B-57F2DCAEE48EQ40161182-E64525DA-5534-4566-9C07-F046CA30F848
P2860
Mortality in schizophrenia: a measurable clinical endpoint
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Mortality in schizophrenia: a measurable clinical endpoint
@ast
Mortality in schizophrenia: a measurable clinical endpoint
@en
Mortality in schizophrenia: a measurable clinical endpoint
@nl
type
label
Mortality in schizophrenia: a measurable clinical endpoint
@ast
Mortality in schizophrenia: a measurable clinical endpoint
@en
Mortality in schizophrenia: a measurable clinical endpoint
@nl
prefLabel
Mortality in schizophrenia: a measurable clinical endpoint
@ast
Mortality in schizophrenia: a measurable clinical endpoint
@en
Mortality in schizophrenia: a measurable clinical endpoint
@nl
P2860
P356
P1476
Mortality in schizophrenia: a measurable clinical endpoint
@en
P2093
Chris J Bushe
Mark Taylor
P2860
P356
10.1177/1359786810382468
P407
P433
P50
P577
2010-11-01T00:00:00Z